LRIG1 is a prognostic biomarker in non-small cell lung cancer

Acta Oncologica

Volumn 54, Issue 8, 2015, Pages 1113-1119

  Kvarnbrink, Samuel ^a   Karlsson, Terese ^a   Edlund, Karolina ^b   Botling, Johan ^b   Lindquist, David ^a   Jirström, Karin ^c   Micke, Patrick ^b   Henriksson, Roger ^a   Johansson, Mikael ^a   Hedman, Håkan ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN LRIG; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; LRIG1 PROTEIN, HUMAN; MEMBRANE PROTEIN; TUMOR MARKER;

AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG ALVEOLUS EPITHELIUM; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOKING; BIOSYNTHESIS; KAPLAN MEIER METHOD; LUNG TUMOR; MORTALITY; PATHOLOGY; PROGNOSIS; TISSUE MICROARRAY;

AGED; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; PROGNOSIS; TISSUE ARRAY ANALYSIS;

EID: 84940479247     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2015.1021427     Document Type: Article

References (27)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Cancer incidence in Sweden 2011 [Internet]. Stockholm: Socialstyrelsen; 2012. Available from: http://www.socialsty- relsen.se
3. Arriagada R, Dunant A, Pignon J-P, Bergman B, Chabowski M, Grunenwald D, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol 2010;28:35-2.
4. Suzuki Y, Sato N, Tohyama M, Wanaka A, Takagi T. cDNA cloning of a novel membrane glycoprotein that is expressed specifically in glial cells in the mouse brain. LIG-1, a protein with leucine-rich repeats and immunoglobulin-like domains. J Biol Chem 1996;271:22522-7.
5. Nilsson J, Vallbo C, Guo D, Golovleva I, Hallberg B, Henriksson R, et al. Cloning, characterization, and expression of human LIG1. Biochem Biophys Res Comm 2001; 284:1155-61.
6. Holmlund C, Nilsson J, Guo D, Starefeldt A, Golovleva I, Henriksson R, et al. Characterization and tissue-specific expression of human LRIG2. Gene 2004;332:35-43.
7. Guo D, Holmlund C, Henriksson R, Hedman H. The LRIG gene family has three vertebrate paralogs widely expressed in human and mouse tissues and a homolog in Ascidiacea. Genomics 2004;84:157-65.
8. Powell AE, WangY, LiY, Poulin EJ, Means AL, Washington MK, et al. The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. Cell 2012;149:146-58.
9. Lu L, Teixeira VH, Yuan Z, Graham TA, Endesfelder D, Kolluri K, et al. LRIG1 regulates cadherin-dependent contact inhibition directing epithelial homeostasis and pre-invasive squamous cell carcinoma development. J Pathol 2013;229: 608-20.
10. WangY, Poulin EJ, Coffey RJ. LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor. Br J Cancer 2013;108:1765-70.
11. Rondahl V, Holmlund C, Karlsson T, Wang B, Faraz M, Henriksson R, et al. Lrig2-deficient mice are protected against PDGFB-induced glioma. PLoS One 2013;8:e73635.
12. Yi W, Holmlund C, Nilsson J, Inui S, Lei T, Itami S, et al. Paracrine regulation of growth factor signaling by shed leu-cine-rich repeats and immunoglobulin-like domains 1. Exp Cell Res 2011;317:504-12.
13. Goldoni S, Iozzo RA, Kay P, Campbell S, Mcquillan A, Agnew C, et al. A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity. Oncogene 2007;26:368-81.
14. Johansson M, Oudin A, Tiemann K, Bernard A, Golebiewska A, Keunen O, et al. The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status. Neuro-Oncology 2013;15:1200-11.
15. Rafidi H, Mercado F, Astudillo M, Fry WHD, Saldana M, Carraway KL, et al. Leucine-rich repeat and immunoglobu-lin domain-containing protein-1 (Lrig1) negative regulatory action toward ErbB receptor tyrosine kinases is opposed by leucine-rich repeat and immunoglobulin domain-containing protein 3 (Lrig3). J Biol Chem 2013;288: 21593-605.
16. Lindquist D, Kvarnbrink S, Henriksson R, Hedman H. LRIG and cancer prognosis. Acta Oncol 2014;53:1135-2.
17. Rouam S, Moreau T, Broet P. Identifying common prognostic factors in genomic cancer studies: A novel index for censored outcomes. BMC Bioinformatics 2010;11:150.
18. Wang G, Wu J, Song H. LRIG2 expression and prognosis in non-small cell lung cancer. Oncol Lett 2014;8:667-72.
19. Boelens MC, van den Berg A, Fehrmann RSN, Geerlings M, de Jong WK, Meerman te GJ, et al. Current smoking-specific gene expression signature in normal bronchial epithelium is enhanced in squamous cell lung cancer. J Pathol 2009; 218:182-91.
20. Ostroff RM, Bigbee WL, Franklin W, Gold L, Mehan M, Miller YE, et al. Unlocking biomarker discovery: Large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS One 2010;5:e15003.
21. Botling J, Edlund K, Lohr M, Hellwig B, Holmberg L, Lambe M, et al. Biomarker discovery in non-small cell lung cancer: Integrating gene expression profiling, meta-analysis, and tissue microarray validation. Clin Cancer Res 2013;19:194-204.
22. Holmlund C, Nilsson J, Guo D, Starefeldt A, Golovleva I, Henriksson R, et al. Characterization and tissue-specific expression of human LRIG2. Gene 2004;332: 35-43.
23. Guo D, Nilsson J, Haapasalo H, Raheem O, Bergenheim T, Hedman H, et al. Perinuclear leucine-rich repeats and immu-noglobulin-like domain proteins (LRIG1-3) as prognostic indicators in astrocytic tumors. Acta Neuropathol 2006;111:238-46.
24. Nilsson J, Starefeldt A, Henriksson R, Hedman H. LRIG1 protein in human cells and tissues. Cell Tissue Res 2003; 312:65-71.
25. Tanemura A, Nagasawa T, Inui S, Itami S. LRIG-1 provides a novel prognostic predictor in squamous cell carcinoma of the skin: Immunohistochemical analysis for 38 cases. Dermatol Surg 2005;31:423-30.
26. Thompson PA, Ljuslinder I, Tsavachidis S, Brewster A, Sahin A, Hedman H, et al. Loss of LRIG1 locus increases risk of early and late relapse of stage I/II breast cancer. Cancer Res 2014;74:2928-35.
27. Lindstrom AK, Ekman K, Stendahl U, Tot T, Henriksson R, Hedman H, et al. LRIG1 and squamous epithelial uterine cervical cancer: Correlation to prognosis, other tumor markers, sex steroid hormones, and smoking. Int J Gynecol Cancer 2008;18:312-7.